53.30

3.13% -1.65

Crinetics Pharmaceuticals Inc (CRNX)

Overview News Price History Option Chain Financials Why CRNX Down? Discussions Forecast

Crinetics Pharmaceuticals Inc stock is traded at $53.30, with a volume of 572.56K. It is down -3.13% in the last 24 hours and up +8.92% over the past month. Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

Previous Close:

$54.95

Open:

$54.9

24h Volume:

572.56K

Relative Volume:

0.43

Market Cap:

$5.46B

Revenue:

$4.72M

Net Income/Loss:

$-277.91M

P/E Ratio:

-14.29

EPS:

-3.73

Net Cash Flow:

$-203.56M

1W Performance:

-4.93%

1M Performance:

+8.92%

6M Performance:

+71.82%

1Y Performance:

+35.79%

1-Day Range:

$52.94

$55.27

1-Week Range:

$52.94

$56.99

52-Week Range:

$24.10

$57.99

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Name

Crinetics Pharmaceuticals Inc

Sector

Healthcare (1119)

Industry

Biotechnology (625)

Phone

858-450-6464

Address

6055 LUSK BLVD., SAN DIEGO, CA

Employee

437

Twitter

@Crinetics

Next Earnings Date

2024-11-12

Latest SEC Filings

CRNX's Discussions on Twitter

Compare CRNX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRNX Crinetics Pharmaceuticals Inc	53.30	5.63B	4.72M	-277.91M	-203.56M	-3.73
VRTX Vertex Pharmaceuticals Inc	466.03	118.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	752.27	79.40B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	816.66	51.18B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	362.64	48.88B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	339.31	37.49B	4.98B	69.59M	525.67M	0.5197

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-26	Upgrade	Goldman	Neutral → Buy
Jul-10-25	Initiated	Goldman	Neutral
Mar-25-25	Initiated	Stifel	Buy
Feb-11-25	Initiated	TD Cowen	Buy
Feb-04-25	Initiated	Wolfe Research	Peer Perform
Jan-22-25	Upgrade	Jefferies	Hold → Buy
Mar-06-24	Initiated	Citigroup	Buy
Jan-16-24	Initiated	Morgan Stanley	Overweight
Dec-21-23	Initiated	Jefferies	Hold
Nov-20-23	Resumed	JP Morgan	Overweight
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Aug-31-23	Initiated	Oppenheimer	Outperform
Apr-24-23	Initiated	Piper Sandler	Overweight
Mar-30-23	Initiated	Robert W. Baird	Outperform
Nov-30-21	Initiated	JMP Securities	Mkt Outperform
Nov-23-21	Initiated	Evercore ISI	Outperform
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-23-19	Initiated	ROTH Capital	Buy
Feb-14-19	Initiated	H.C. Wainwright	Buy
Aug-13-18	Initiated	JP Morgan	Neutral
Aug-13-18	Initiated	Leerink Partners	Outperform
Aug-13-18	Initiated	Piper Jaffray	Overweight

View All

Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News

02:00 AM

Crinetics begins phase 2/3 trial of oral CAH treatment in children - Investing.com Nigeria

02:00 AM

Jan 22, 2026

Crinetics (CRNX) Launches Phase 2/3 Trial for Atumelnant in Pedi - GuruFocus

Jan 22, 2026

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) - GlobeNewswire

Jan 22, 2026

Jim Cramer on Crinetics: “That’s a Better Spec Than Aquestive” - Insider Monkey

Jan 22, 2026

Jan 18, 2026

Goldman Sachs upgrades Crinetics Pharmaceuticals, Inc. (CRNX) to buy from neutral - MSN

Jan 18, 2026

Jan 16, 2026

A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Goldman Sachs Upgrade And Palsonify Atumelnant Progress - Sahm

Jan 16, 2026

Jan 15, 2026

Retail Surge: What is the dividend yield of Crinetics Pharmaceuticals Inc2025 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn

Jan 15, 2026

Crinetics Pharmaceuticals exec sells shares worth $195,350 - MSN

Jan 15, 2026

Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral - Insider Monkey

Jan 15, 2026

Jan 14, 2026

Hedge Fund Bets: Can Crinetics Pharmaceuticals Inc be recession proofEarnings Risk Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn

Jan 14, 2026

Jan 13, 2026

Why Crinetics Pharmaceuticals (CRNX) Is Up 18.2% After Equity Raise and PALSONIFY, Atumelnant Updates - Sahm

Jan 13, 2026

Crinetics Pharmaceuticals discovers new SSTR2 non-peptide-drug conjugates - BioWorld MedTech

Jan 13, 2026

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Jan 13, 2026

Jan 12, 2026

Goldman Sachs Upgrades Crinetics Pharmaceuticals (CRNX) - Nasdaq

Jan 12, 2026

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jan 12, 2026

CRNX Upgraded to 'Buy' by Goldman Sachs with New Price Target of $67 | CRNX Stock News - GuruFocus

Jan 12, 2026

Crinetics Shares Rise After Goldman Sachs Upgrade - marketscreener.com

Jan 12, 2026

The Goldman Sachs Group Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy - MarketBeat

Jan 12, 2026

Crinetics stock rating upgraded by Goldman Sachs on promising CAH drug data - Investing.com Canada

Jan 12, 2026

10 new Crinetics workers get stock awards vesting over 4 years - Stock Titan

Jan 12, 2026

Jan 10, 2026

Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data - Yahoo Finance

Jan 10, 2026